Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.
Perspectum

Perspectum Diagnostics, a spinout company from the Radcliffe Department of Medicine, has reinvested money into research at the University of Oxford, to fund a three year multicentre European health economic study into methods of diagnosing fatty liver disease. This first of three payments totalling €759,999, is part of a €3.4m project, won by Perspectum in the EU Horizon 2020 grant competition.

Perspectum Diagnostics has developed an MRI scanning technique to detect and monitor non-alcoholic fatty liver disease (NAFLD) – a growing concern due to its links with obesity and diabetes. LiverMultiScan offers a safe and non-invasive method to aid diagnosis of liver disorders. Patients are already benefitting from the technology, which was introduced in Europe and the U.S. as a research device in 2014. It has now been made available in leading medical institutions in 50 hospitals, globally.

Researchers in the Health Economics Research Centre (HERC) at the Nuffield Department of Population Health will conduct the study, comparing the cost of patient care using liver biopsy with that of using LiverMultiScan. 

2,000 patients with a suspected diagnosis of NAFLD will be recruited to centres in Germany, the Netherlands and Portugal. Each patient will be randomised to either follow the current diagnostic pathway with biopsy, or to have early access to state-of-the-art MRI with LiverMultiScan, to determine the presence and extent of disease. At the end of the trial, the cost-effectiveness and patient-reported outcome measures of the two diagnostic pathways will be compared.

Oxford University researchers have already published clinical studies which show how multiparametric MRI scans help in the diagnostic pathway for liver diseases (Banerjee et al, 2014) and can identify which patients are at risk of liver failure (Pavlides, et al, 2016).

Perspectum Diagnostics was founded less than 5 years ago, based in part on intellectual property generated in the Radcliffe Department of Medicine, and which was licensed to Perspectum through the University’s Technology Transfer department – Oxford University Innovation.  The company has continued to enjoy mutually beneficial scientific relationships with the Oxford Centre for Clinical Magnetic Resonance Research (OCMR), benefitting in particular from the scientific leadership of Professors Neubauer and Robson. The company now employs 50 people in the UK and the US, many of them alumni of the University.